BCRX - バイオクリスト・ファ―マシュ―ティカルズ (BioCryst Pharmaceuticals Inc.) バイオクリスト・ファ―マシュ―ティカルズ

 BCRXのチャート


 BCRXの企業情報

symbol BCRx
会社名 BioCryst Pharmaceuticals Inc (バイオクリスト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 バイオクリスト・ファーマシューティカルズ(BioCryst Pharmaceuticals Inc.)はバイオテクノロジー企業である。病気の病因に関与する酵素をブロックする小分子薬の設計、最適化と開発を行う。同社は希少疾患の治療に集中する。同社はX線結晶学、分子構造のコンピュータモデリングと化学技術を利用して細胞生物学を制御する酵素の活性部位特性と三次元的な分子構造の解明に集中する。同社の薬剤候補はRAPIVAB、RAPIACTA、ALPIVAB、PERAMIFLU、Avoralstat、BCX7353、他の第二世代遺伝性血管浮腫(HAE)化合物、GalidesivirとForodesineなどを含む。同社の製品RAPIVABはペラミビルを含む。ALPIVABは静脈内ノイラミニダーゼ阻害剤である。Galidesivirは出血熱ウイルスの治療に向けの広域抗ウイルス(BSAV)研究プログラムである。Forodesineはがん治療薬としてMundipharmaによる開発されたプリンヌクレオシドホスホリラーゼ(PNP)阻害剤である。   バイオクリスト・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。疾患の発症を引き起こす酵素を阻害する薬剤の開発に従事。インフルエンザ患者の治療薬ペラミビル、痛風治療薬ウロデシン、血液学的悪性腫瘍の治療薬フォロデシン、遺伝性血管性浮腫(HAE)の治療薬BCX4161などの開発を行う。またエボラウィルスの治療用抗ウィルスの研究を手掛ける。   
本社所在地 4505 Emperor Blvd. Suite 200 Durham NC 27703 USA
代表者氏名 Robert A. Ingram ロバートA.イングラム
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 919-859-1302
設立年月日 1986年
市場名 NASDAQ National Market System
ipoyear 1994年
従業員数 85人
url www.biocryst.com
nasdaq_url https://www.nasdaq.com/symbol/bcrx
adr_tso
EBITDA EBITDA(百万ドル) -70.93800
終値(lastsale) 6.79
時価総額(marketcap) 744144753.8
時価総額 時価総額(百万ドル) 745.24070
売上高 売上高(百万ドル) 29.12000
企業価値(EV) 企業価値(EV)(百万ドル) 716.19070
当期純利益 当期純利益(百万ドル) -78.90000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 BioCryst Pharmaceuticals Inc. revenues increased 31% to $16.5M. Net loss increased 42% to $44.2M. Revenues reflect Collaborative and other research and dev increase from $5.7M to $12.7M. Higher net loss reflects General_Administrative increase from $5.9M to $17.1M (expense) Research and development increase of 21% to $39.5M (expense).

 BCRXのテクニカル分析


 BCRXのニュース

   BCRX Stock: BioCryst Pharmaceutcials Announces ORLADEYO Launch  2020/12/16 13:42:38 CNA Finance
BCRX stock is headed for the top in the market this morning after announcing that ORLADEYO is now commercially available.
   BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) VP Alane P. Barnes Sells 13,741 Shares  2020/12/16 11:36:42 Watchlist News
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) VP Alane P. Barnes sold 13,741 shares of the firm’s stock in a transaction that occurred on Friday, December 11th. The shares were sold at an average price of $7.96, for a total transaction of $109,378.36. Following the completion of the transaction, the vice president now directly owns 121,802 shares of […]
   BioCryst to Present at JMP Securities Hematology Summit  2020/12/11 12:00:00 GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will…
   Merrill Lynch Stick to Their Buy Rating for Biocryst Pharmaceuticals  2020/12/08 09:55:23 Investing.com
Merrill Lynch Stick to Their Buy Rating for Biocryst Pharmaceuticals
   Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals  2020/12/07 13:45:00 GlobeNewswire
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…
   What Does BioCryst Pharmaceuticals's Debt Look Like?  2020/11/13 07:59:00 Benzinga
Over the past three months, shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) decreased by 4.88%. Before we understand the importance of debt, let us look …
   BioCryst to Present Data at the 2020 ASH Annual Meeting  2020/11/12 12:00:00 GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that preclinical data on…
   BioCryst Pharmaceuticals : MHRA Grants HAE Patients Early Access to BioCryst's Berotralstat in United Kingdom | MarketScreener  2020/10/30 12:16:09 MarketScreener
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2020 -- BioCryst Pharmaceuticals, Inc. today announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency has granted oral,… | October 30, 2020
   BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 7%  2020/10/22 18:52:50 US Banking News
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price traded up 7% during mid-day trading on Thursday . The company traded as high as $3.84 and last traded at $3.84. 5,101,051 shares changed hands during mid-day trading, a decline of 31% from the average session volume of 7,371,685 shares. The stock had previously closed at $3.59. A number […]
   BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 7.3%  2020/10/21 11:52:49 Dakota Financial News
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) fell 7.3% during trading on Monday . The company traded as low as $3.54 and last traded at $3.57. 7,000,342 shares were traded during trading, a decline of 6% from the average session volume of 7,414,611 shares. The stock had previously closed at $3.85. A number of brokerages have […]
   What Does BioCryst Pharmaceuticals's Debt Look Like?  2020/11/13 07:59:00 Benzinga
Over the past three months, shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) decreased by 4.88%. Before we understand the importance of debt, let us look …
   BioCryst to Present Data at the 2020 ASH Annual Meeting  2020/11/12 12:00:00 GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that preclinical data on…
   BioCryst Pharmaceuticals : MHRA Grants HAE Patients Early Access to BioCryst's Berotralstat in United Kingdom | MarketScreener  2020/10/30 12:16:09 MarketScreener
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2020 -- BioCryst Pharmaceuticals, Inc. today announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency has granted oral,… | October 30, 2020
   BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 7%  2020/10/22 18:52:50 US Banking News
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price traded up 7% during mid-day trading on Thursday . The company traded as high as $3.84 and last traded at $3.84. 5,101,051 shares changed hands during mid-day trading, a decline of 31% from the average session volume of 7,371,685 shares. The stock had previously closed at $3.59. A number […]
   BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 7.3%  2020/10/21 11:52:49 Dakota Financial News
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) fell 7.3% during trading on Monday . The company traded as low as $3.54 and last traded at $3.57. 7,000,342 shares were traded during trading, a decline of 6% from the average session volume of 7,414,611 shares. The stock had previously closed at $3.85. A number of brokerages have […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バイオクリスト・ファ―マシュ―ティカルズ BCRX BioCryst Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)